Andrea Olariu
COO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrea Olariu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:49 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03642210 · Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual BleedingMedicines360 · completed · Menorrhagia · study director
- Ph3NCT00995150 · A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible ContraceptionMedicines360 · terminated · Contraception · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:49 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery.Circulation · 2004203 citationsRCR 5.2
- Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System.Obstet Gynecol · 201939 citationsRCR 3.2
- Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system.Contraception · 201627 citationsRCR 1.3
- Bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system.Eur J Contracept Reprod Health Care · 201821 citationsRCR 1.6
- Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use.Contraception · 201819 citationsRCR 1.3
- Relationship of parity and prior cesarean delivery to levonorgestrel 52 mg intrauterine system expulsion over 6 years.Contraception · 20219 citationsRCR 0.8
- Conception rates in women desiring pregnancy after levonorgestrel 52 mg intrauterine system (Liletta®) discontinuation.Contraception · 20216 citationsRCR 0.6
- Levonorgestrel 52-mg Intrauterine Device Efficacy and Safety After More Than 8 Years of Use.Obstet Gynecol · 20235 citationsRCR 1.1